Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II marker identification trial of Tarceva in second-line NSCLC
2004-005096-42Phase 2Completed
- Sponsor
- Roche
- Start
- May 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of erlotinib in non-small cell lung cancer (NSCLC), sponsored by Roche. Started May 2005; status: completed.
02
Drugs
erlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2004-005096-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-005096-42.